SNY — Sanofi catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

12 verified catalyst event(s) for Sanofi (ticker SNY). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-08-08 — A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-08-08 in 2d ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-25 in 19d ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Partici Phase 2 · Graves' Disease	SNY Sanofi	Rilzabrutinib dose 1, Rilzabrutinib dose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-27 in 21d ESTIMATED	READOUT Teplizumab in Pediatric Stage 2 Type 1 Diabetes Phase 4 · Diabetes Mellitus, Type 1	SNY Sanofi	teplizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-09-29 in 2mo ESTIMATED	READOUT Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa Phase 2 · Asthma	SNY Sanofi	Amlitelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-14 in 2mo ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-06 in 3mo ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-30 in 4mo ESTIMATED	READOUT Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha Phase 3 · Immune Thrombocytopenia	SNY Sanofi	rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-01 in 4mo ESTIMATED	READOUT A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Partic Phase 3 · Chronic Obstructive Pulmonary Disease	SNY Sanofi	Itepekimab (SAR440340)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-01 in 4mo ESTIMATED	READOUT Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Phase 3 · Pneumococcal Infections	SNY Sanofi	PCV21, 20vPCV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-01 in 4mo ESTIMATED	READOUT Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers	SNY Sanofi	Pandemic flu H5 HA mRNA SD2 vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-17 in 4mo ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Phase 2 · Crohn's Disease	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-12-17 in 4mo ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participant Phase 2 · Ulcerative Colitis	SNY Sanofi	SAR442970	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change